Screening methods for influenza antiviral drug discovery

Expert Opinion on Drug Discovery

Volumn 7, Issue 5, 2012, Pages 429-438

  Atkins, Colm ^a,b   Evans, Carrie W ^a   White, E Lucile ^a   Noah, James W ^a,b  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Drug discovery; High throughput screening; Host targets; HTS; Influenza; Influenza antivirals; Influenza drug targets

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; DNA POLYMERASE; HN PROTEIN; HOLOENZYME; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; LANINAMIVIR; NONSTRUCTURAL PROTEIN 1; NONSTRUCTURAL PROTEIN 2; NUCLEOPROTEIN; OSELTAMIVIR; PERAMIVIR; POLYMERASE SUBUNIT PA; POLYMERASE SUBUNIT PB1; POLYMERASE SUBUNIT PB2; PROTEIN M2; RIMANTADINE; SIALIC ACID DERIVATIVE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS SIALIDASE; ZANAMIVIR;

ANTIVIRAL ACTIVITY; AVIAN INFLUENZA; AVIAN INFLUENZA VIRUS; BIOASSAY; CELL ASSAY; CELL PROTECTION; DRUG DESIGN; DRUG DETERMINATION; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; GENE MAPPING; GROWTH INHIBITION; HIGH THROUGHPUT SCREENING; HOST PATHOGEN INTERACTION; HUMAN; INFLUENZA; INFLUENZA VIRUS; MICROARRAY ANALYSIS; MOLECULAR DOCKING; MOLECULAR LIBRARY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN RNA BINDING; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA INTERFERENCE; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS STRAIN; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTIVIRAL AGENTS; DOGS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HEK293 CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 84860379191     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2012.674510     Document Type: Review

References (63)

1. The Molecular Libraries Program. Available from: Http://mlinihgov/mli/ mlpcn/ [Accessed 19 January 2012]
2. Innovative Medicines Initiative. Available from: Http://wwwimieuropaeu/ content/5th-call-2012 [Accessed 19 January 2012]
3. European Infrastructure of Open Screening Platforms for Chemical Biology. Available from: Http://wwweu-openscreeneu/ [Accessed 19 January 2012]
4. Centers for Disease Control and Prevention. Available from: Http://www. cdc.gov/nchs/fastats/lcod.htm 2010.[Accessed 5 March 2012]
5. Szucs T. The socio-economic burden of influenza. J Antimicrob Chemother 1999;44(Suppl B):11-15 (Pubitemid 29531319)
6. Hay AJ, Gregory V, Douglas AR, et al. The evolution of human influenza viruses. Philos Trans R Soc Lond B Biol Sci 2001;356(1416):1861-70 (Pubitemid 34099091)
7. Smith GJ, Vijaykrishna D, Bahl J, et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 2009;459(7250):1122-5
8. Matsuzaki Y, Sugawara K, Mizuta K, et al. Antigenic and genetic characterization of influenza C viruses which caused two outbreaks in Yamagata City, Japan, in 1996 and 1998. J Clin Microbiol 2002;40(2):422-9
9. Sittampalam S, Eastwood B, Iturria S, et al. Assay Guidance Manual. Available from: Http://assaynihgov/assay/indexphp/Table-of-Contents 2012.[Accessed 1 March 2012]
10. Noah DL, While EL, Noah JW. Development of high-Throughput screening assays for influenza. In: Torrence PF, editor. Combating the Threat of Pandemic Influenza: Drug Discovery Approaches. John Wiley & Sons, Inc; Hoboken, NJ: 2007. p. 38-72
11. Stevens J, Blixt O, Paulson JC, et al. Glycan microarray technologies: Tools to survey host specificity of influenza viruses. Nat Rev Microbiol 2006;Nov4(11):857-64 (Pubitemid 44593952)
12. Szecsi J, Drury R, Josserand V, et al. Targeted retroviral vectors displaying a cleavage site-engineered hemagglutinin (HA) through HA-protease interactions. Mol Ther 2006;14(5):735-44 (Pubitemid 44480752)
13. Ferrer M, Kapoor TM, Strassmaier T, et al. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. Nat Struct Biol 1999;6(10):953-60 (Pubitemid 29463310)
14. Blick TJ, Tiong T, Sahasrabudhe A, et al. Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en. Virology 1995;214(2):475-84 (Pubitemid 26027775)
15. Kongkamnerd J, Milani A, Cattoli G, et al. A screening assay for neuraminidase inhibitors using neuraminidases N1 and N3 from a baculovirus expression system. J Enzyme Inhib Med Chem 2011;27(1):5-11
16. Noah DL, Krug RM. Influenza virus virulence and its molecular determinants. Adv Virus Res 2005;65:121-45 (Pubitemid 43574762)
17. Chien CY, Xu Y, Xiao R, et al. Biophysical characterization of the complex between double-stranded RNA and the N-Terminal domain of the NS1 protein from influenza A virus: Evidence for a novel RNA-binding mode. Biochemistry 2004;43(7):1950-62 (Pubitemid 38233257)
18. Li S, Min JY, Krug RM, et al. Binding of the influenza A virus NS1 protein to PKR mediates the inhibition of its activation by either PACT or double-stranded RNA. Virology 2006;349(1):13-21
19. Maroto M, Fernandez Y, Ortin J, et al. Development of an HTS assay for the search of anti-influenza agents targeting the interaction of viral RNA with the NS1 protein. J Biomol Screen 2008;13(7):581-90
20. Cho EJ, Xia S, Ma LC, et al. Identification of Influenza virus inhibitors targeting NS1A utilizing fluorescence polarization-based high-Throughput assay. J Biomol Screen January 5, 2012. doi:10.1177/1087057111431488
21. You L, Cho EJ, Leavitt J, et al. Synthesis and evaluation of quinoxaline derivatives as potential influenza NS1A protein inhibitors. Bioorg Med Chem Lett 2011;21(10):3007-11
22. Southern Research Specialized Biocontaiment Screening Center. Discovery of Small Molecule Probes for H1N1 Influenza NS1A. Available from: Http://pubchemncbinlmnihgov/assay/assaycgi?aid=504399&loc=ea-ras2012
23. Hooker L, Sully R, Handa B, et al. Quantitative analysis of influenza virus RNP interaction with RNA cap structures and comparison to human cap binding protein eIF4E. Biochemistry 2003;42(20):6234-40 (Pubitemid 36605126)
24. Newcomb LL, Kuo RL, Ye Q, et al. Interaction of the influenza a virus nucleocapsid protein with the viral RNA polymerase potentiates unprimed viral RNA replication. J Virol 2009;83(1):29-36
25. Baughman BM, Slavish P, Dubois RM, et al. Identification of influenza endonuclease inhibitors using a novel fluorescence polarization assay. ACS Chem Biol 2012;7(3):526-34
26. McCoy MH, Wang E. Use of electric cell-substrate impedance sensing as a tool for quantifying cytopathic effect in influenza A virus infected MDCK cells in real-Time. J Virol Methods 2005;130(1-2):157-61 (Pubitemid 41596999)
27. Noah JW, Severson W, Noah DL, et al. A cell-based luminescence assay is effective for high-Throughput screening of potential influenza antivirals. Antiviral Res 2007;73(1):50-9 (Pubitemid 46080478)
28. Severson WE, McDowell M, Ananthan S, et al. High-Throughput screening of a 100,000-compound library for inhibitors of influenza A virus (H3N2). J Biomol Screen 2008;13(9):879-87
29. Maddry JA, Chen X, Jonsson CB, et al. Discovery of novel benzoquinazolinones and thiazoloimidazoles, inhibitors of influenza H5N1 and H1N1 viruses, from a cell-based high-Throughput screen. J Biomol Screen 2010;16(1):73-81
30. Matrosovich M, Matrosovich T, Garten W, et al. New low-viscosity overlay medium for viral plaque assays. Virol J 2006;3:63
31. Sullivan K, Kloess J, Qian C, et al. High throughput virus plaque quantitation using a flatbed scanner. J Virol Methods 2012;179(1):81-9
32. Huber I, Campe H, Sebah D, et al. A multiplex one-step real-Time RT-PCR assay for influenza surveillance. Euro Surveill 2011;16(7):19798-805
33. Zhang J, Liu T, Tong X, et al. Identification of novel virus inhibitors by influenza A virus specific reporter cell based screening. Antiviral Res 2012;93(1):48-54
34. Ghanem A, Mayer D, Chase G, et al. Peptide-mediated interference with influenza A virus polymerase. J Virol 2007;81(14):7801-4 (Pubitemid 47047866)
35. Cairns MJ, Sun LQ. Nucleic acid sequence analysis using DNAzymes. Methods Mol Biol 2004;252:291-302
36. Watanabe T, Watanabe S, Kawaoka Y. Cellular networks involved in the influenza virus life cycle. Cell Host Microbe 2010;7(6):427-39
37. Konig R, Stertz S, Zhou Y, et al. Human host factors required for influenza virus replication. Nature 2010;463(7282):813-17
38. Karlas A, Machuy N, Shin Y, et al. Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication. Nature 2010;463(7282):818-22
39. Lietzen N, Ohman T, Rintahaka J, et al. Quantitative subcellular proteome and secretome profiling of influenza A virus-infected human primary macrophages. PLoS Pathog 2011;7(5):e1001340
40. Liu L, Li R, Pan Y, et al. High-Throughput screen of protein expression levels induced by cyclooxygenase-2 during influenza a virus infection. Clin Chim Acta 2012;412(11-12):1081-5
41. Tscherne DM, Garcia-Sastre A. An enzymatic assay for detection of viral entry. Curr Protoc Cell Biol 2011; Chapter 26:Unit 26 12
42. Pinto LH, Lamb RA. Viral ion channels as models for ion transport and targets for antiviral drug action. FEBS Lett 2004;560(1-3):1-2 (Pubitemid 38264282)
43. Bright RA, Shay DK, Shu B, et al. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. Jama 2006;295(8):891-4
44. Perkel JM. High-Throughput ion channel screening: A "patch"- work solution. Biotechniques 2010;48(1):25-9
45. Das K, Aramini JM, Ma LC, et al. Structures of influenza A proteins and insights into antiviral drug targets. Nat Struct Mol Biol 2010;17(5):530-8
46. Babu YS, Chand P, Bantia S, et al. BCX-1812 (RWJ-270201): Discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem 2000;43(19):3482-6
47. Grienke U, Schmidtke M, von Grafenstein S, et al. Influenza neuraminidase: A druggable target for natural products. Nat Prod Rep 2011;29(1):11-36
48. Lew W, Chen X, Kim CU. Discovery and development of GS 4104 (oseltamivir): An orally active influenza neuraminidase inhibitor. Curr Med Chem 2000;7(6):663-72 (Pubitemid 30396423)
49. von Itzstein M, Wu WY, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993;363(6428):418-23 (Pubitemid 23179386)
50. Yamashita M, Tomozawa T, Kakuta M, et al. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-Acting anti-influenza virus activity. Antimicrob Agents Chemother 2009;53(1):186-92
51. Coloma R, Valpuesta JM, Arranz R, et al. The structure of a biologically active influenza virus ribonucleoprotein complex. PLoS Pathog 2009;5(6):e1000491
52. Ng AK, Zhang H, Tan K, et al. Structure of the influenza virus A H5N1 nucleoprotein: Implications for RNA binding, oligomerization, and vaccine design. FASEB J 2008;22(10):3638-47
53. Russell RJ, Kerry PS, Stevens DJ, et al. Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc Natl Acad Sci USA 2008;105(46):17736-41
54. Schnell JR, Chou JJ. Structure and mechanism of the M2 proton channel of influenza A virus. Nature 2008;451(7178):591-5 (Pubitemid 351186272)
55. Xia S, Monzingo AF, Robertus JD. Structure of NS1A effector domain from the influenza A/Udorn/72 virus. Acta Crystallogr D Biol Crystallogr 2009;65(Pt 1):11-17
56. Fukuoka M, Minakuchi M, Kawaguchi A, et al. Structure-based discovery of anti-influenza virus A compounds among medicines. Biochim Biophys Acta 2011;1820(2):90-5
57. Fedichev P, Timakhov R, Pyrkov T, et al. Structure-based drug design of a new chemical class of small molecules active against influenza A nucleoprotein in vitro and in vivo. PLoS Curr 2011;3:RRN1253
58. Pan D, Sun H, Shen Y, et al. Exploring the molecular basis of dsRNA recognition by NS1 protein of influenza A virus using molecular dynamics simulation and free energy calculation. Antiviral Res 2011;92(3):424-33
59. World Health Organization. Table on Clinical trials of pandemic and potentially pandemic influenza vaccines. Available from: Http://www.who.int/ vaccine-research/diseases/influenza/flu-Trials-Tables/en/2011.[Accessed 13 January 2012]
60. Centers for Disease Control and Prevention. Available from: Http://www. cdc.gov/flu/h2n2backgroundqa.htm 2006.[Accessed 3 January 2012]
61. Ludwig S, Pleschka S, Planz O, et al. Ringing the alarm bells: Signalling and apoptosis in influenza virus infected cells. Cell Microbiol 2006;8(3):375-86 (Pubitemid 43356029)
62. Ludwig S, Wolff T. Influenza A virus TRIMs the type I interferon response. Cell Host Microbe 2009;5(5):420-1
63. World Health Organization. WHO activities in avian influenza and pandemic influenza preparedness. Available from: Http://www.who.int/influenza/resources/ documents/WHO-CDS-EPR-GIP-2006-6.pdf 2007 [Accessed 3 January 2012]